Long-term efficacy of a triptorelin 3-month depot in girls with central precocious puberty
3
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Three-month gonadotropin-releasing hormone agonists (GnRHas) are expected to achieve better compliance in patients with central precocious puberty (CPP) compared to the monthly formulation. However, 1-month depot remains the dominant choice for conventional treatment worldwide. Our study aimed to investigate the long-term efficacy of a 3-month GnRHa for CPP treatment.Methods: In this retrospective study, 69 Korean girls with CPP were prescribed either triptorelin pamoate (TP) 3-month depot (n=29) or triptorelin acetate (TA) 1-month depot (n=40) and were followed for 1 year after the end of treatment. Auxological, radiological, and biochemical data were collected every 6 months.Results: Baseline characteristics were similar between the 2 groups. In the TP 3-month depot group, 27 of 29 patients (93.1%) exhibited suppressed luteinizing hormone level (below 2.5 IU/L) after 6 months of treatment, and this suppression level was reserved until the final injection. The degree of bone age advancement in the TP 3-month depot group decreased from 1.8±0.4 years at the start of treatment to 0.6±0.5 years at 1-year posttreatment. The gain in predicted adult height (PAH) 1 year after the end of treatment was similar between the TP 3-month and TA 1-month depot groups (5.2±3.1 and 5.3±2.4 cm, respectively; <i>p</i>=0.875).Conclusion: A 3-month depot of triptorelin effectively inhibited gonadal and sex hormones, suppressed bone maturation, and increased PAH. For patient convenience, we suggest a 3-month GnRHa regimen as a promising CPP treatment option.
Abstract
Purpose: Three-month gonadotropin-releasing hormone agonists (GnRHas) are expected to achieve better compliance in patients with central precocious puberty (CPP) compared to the monthly formulation. However, 1-month depot remains the dominant choice for conventional treatment worldwide. Our study aimed to investigate the long-term efficacy of a 3-month GnRHa for CPP treatment.Methods: In this retrospective study, 69 Korean girls with CPP were prescribed either triptorelin pamoate (TP) 3-month depot (n=29) or triptorelin acetate (TA) 1-month depot (n=40) and were followed for 1 year after the end of treatment. Auxological, radiological, and biochemical data were collected every 6 months.Results: Baseline characteristics were similar between the 2 groups. In the TP 3-month depot group, 27 of 29 patients (93.1%) exhibited suppressed luteinizing hormone level (below 2.5 IU/L) after 6 months of treatment, and this suppression level was reserved until the final injection. The degree of bone age advancement in the TP 3-month depot group decreased from 1.8±0.4 years at the start of treatment to 0.6±0.5 years at 1-year posttreatment. The gain in predicted adult height (PAH) 1 year after the end of treatment was similar between the TP 3-month and TA 1-month depot groups (5.2±3.1 and 5.3±2.4 cm, respectively; <i>p</i>=0.875).Conclusion: A 3-month depot of triptorelin effectively inhibited gonadal and sex hormones, suppressed bone maturation, and increased PAH. For patient convenience, we suggest a 3-month GnRHa regimen as a promising CPP treatment option.
참고문헌 (29)
- Carel JC, "Consensus statement on the use of gonadotropin-releasing hormone analogs in children", Pediatrics, 123, pp.e752~62 (2009)
- Baek JW, "Age of menarche and near adult height after long-term gonadotropin-releasing hormone agonist treatment in girls with central precocious puberty", Ann Pediatr Endocrinol Metab, 19, pp.27~31 (2014)
- Kim YJ, "Incidence and prevalence of central precocious puberty in Korea : an epidemiologic study based on a national database", J Pediatr, 208, pp.221~228 (2019)
- Comite F, "Short-term treatment of idiopathic precocious puberty with a long-acting analog of luteinizing-hormonereleasing hormone-a preliminary-report", New Engl J Med, 305, pp.1546~1550 (1981)
- Swerdloff RS, "Superactive gonadotropin-releasing hormone agonists", Annu Rev Med, 34, pp.491~500 (1983)
- Heger S, "Long-term GnRH agonist treatment for female central precocious puberty does not impair reproductive function", Mol Cell Endocrinol, 254-255, pp.217~220 (2006)
- Lazar L, "Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity", J Clin Endocrinol Metab, 92, pp.3483~3489 (2007)
- Chung LY, "Efficacy of triptorelin 3-month depot compared to 1-month depot for the treatment of Korean girls with central precocious puberty in single tertiary center", J Korean Med Sci, 36, pp.e219~ (2021)
- Martinez-Aguayo A, "Treatment of central precocious puberty with triptorelin 11. 25 mg depot formulation", J Pediatr Endocrinol Met, 19, pp.963~970 (2006)
- Carel JC, "Three-month sustained-release triptorelin(11. 25 mg)in the treatment of central precocious puberty", Eur J Endocrinol, 154, pp.119~124 (2006)
- Jeon MJ, "Short-term efficacy of 1-month and 3-month gonadotropin-releasing hormone agonist depots in girls with central precocious puberty", Ann Pediatr Endocrinol Metab, 26, pp.171~177 (2021)
- Yang JM, "Efficacy of leuprorelin 3-month depot(11. 25mg)compared to 1-month depot(3. 75 mg)for central precocious puberty in Chinese girls : a prospective cohort study", Int J Endocrinol, 2022, pp.1043293~ (2022)
- Ramos CO, "Anthropometric, metabolic, and reproductive outcomes of patients with central precocious puberty treated with leuprorelin acetate 3-month depot(11. 25 mg)", J Pediatr Endocrinol Metab, 34, pp.1371~1377 (2021)
- Bertelloni S, "Central precocious puberty : adult height in girls treated with quarterly or monthly gonadotropinreleasing hormone analog triptorelin", Horm Res Paediatr, 84, pp.396~400 (2015)
- Vatopoulou A, "Long-term effects of treatment of central precocious puberty with gonadotropin-releasing hormone analogs every three months", Gynecol Endocrinol, 36, pp.1124~1126 (2020)
- Lasorella S, "Comparison of triptorelin acetate vs triptorelin pamoate in the treatment of central precocious puberty(CPP) : a retrospective study", Gynecol Endocrinol, 36, pp.338~340 (2020)
- Neely EK, "Spontaneous serum gonadotropin concentrations in the evaluation of precocious puberty", J Pediatr, 127, pp.47~52 (1995)
- Kim YM, "Efficacy of a single luteinizing hormone measurement after GnRH agonist administration for therapeutic monitoring of girls with central precocious puberty", Ann Pediatr Endocrinol Metab, 17, pp.153~159 (2012)
- Greulich WW, "Radiologic atlas of skeletal development of the hand and wrist" (1959), Stanford University Press
- Bayley N, "Tables for predicting adult height from skeletal age-revised for use with the Greulich-Pyle hand standards", J Pediatr, 40, pp.423~441 (1952)
- Bhatia S, "Serum luteinizing hormone rises within minutes after depot leuprolide injection : implications for mo nitoring therapy", Pediatrics, 109, pp.E30~ (2002)
- Lee HS, "Luteinizing hormone secretion during gonadotropin-releasing hormone stimulation tests in obese girls with central precocious puberty", J Clin Res Pediatr Endocrinol, 8, pp.392~398 (2016)
- Fu JF, "Impact of BMI on gonadorelin-stimulated LH peak in premenarcheal girls with idiopathic central precocious puberty", Obesity, 23, pp.637~643 (2015)
- Fuld K, "A randomized trial of 1-and 3-month depot leuprolide doses in the treatment of central precocious puberty", J Pediatr, 159, pp.982~987 (2011)
- Guaraldi F, "Long-term outcomes of the treatment of central precocious puberty", Eur J Endocrinol, 174, pp.R79~R87 (2016)
- Brauner R, "Adult height in girls with idiopathic true precocious puberty", J Clin Endocrinol Metab, 79, pp.415~420 (1994)
- Oostdijk W, "Final height in central precocious puberty after long term treatment with a slow release GnRH agonist", Arch Dis Child, 75, pp.292~297 (1996)
- Arrigo T, "Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty", Eur J Endocrinol, 141, pp.140~144 (1999)
- Klein KO, "Increased final height in precocious puberty after long-term treatment with LHRH agonists : the National Institutes of Health experience", J Clin Endocrinol Metab, 86, pp.4711~4716 (2001)